This page is updated frequently with new G Proteins-related patent applications.
|Individualized cancer therapy|
In certain preferred embodiments, the invention provides methods for treating cancer, which comprise (a) obtaining a specimen of cancer tissue from a patient; (b) obtaining a specimen of normal tissue in the proximity of the cancer tissue from such patient; (c) extracting total protein and rna from the cancer tissue and normal tissue; (d) obtaining a protein expression profile of the cancer tissue and normal tissue using 2d dige and mass spectrometry; (e) identifying proteins that are expressed in such cancer tissue at significantly different levels than in the normal tissue; (f) obtaining a gene expression profile of the cancer tissue and normal tissue using microarray technology and comparing the results thereof to the protein expression profile; (g) prioritizing over-expressed proteins by assessing the connectivity thereof to other cancer-related or stimulatory proteins; (h) designing an appropriate rna interference expression cassette to, directly or indirectly, modulate the expression of genes encoding such prioritized proteins; (i) incorporating said cassette into an appropriate delivery vehicle; and (j) providing the patient with an effective amount of the delivery vehicle to directly or indirectly, modify the expression (i.e., production) of such proteins.. .
|Methods and compositions for genomic target enrichment and selective dna sequencing|
It has been established that one or more large double stranded dna fragments (each 2,000 to 40,000 base pairs in size) can be captured and isolated from genomic dna fragments using sequence specific pna hybridization probes. Compositions and methods for enrichment of a multiplicity of long dna sequences selected from the genome of any eukaryote are provided.
|Anti-activin a antibodies and uses thereof|
The disclosure provides compositions and methods relating to or derived from anti-activin a binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin a antibodies that bind human activin a, activin a-binding fragments and derivatives of such antibodies, and activin a-binding polypeptides comprising such fragments.
|Mrka polypeptides, antibodies, and uses thereof|
The present disclosure provides mrka binding proteins, e.g., antibodies or antigen binding fragments thereof that bind to mrka and induce opsonophagocytic killing of klebsiella (e.g., klebsiella pneumoniae). The present disclosure also provides methods of reducing klebsiella (e.g., klebsiella pneumoniae) or treating or preventing klebsiella (e.g., klebsiella pneumoniae) infection in a subject comprising administering mrka binding proteins, e.g., antibodies or antigen-binding fragments thereof, mrka polypeptides, immunogenic fragments thereof, or polynucleotides encoding mrka or immunogenic fragments thereof to the subject..
|Methods of treatment using hemopexin compositions|
The present invention relates generally to a method of purifying proteins. More specifically, the present inventions relates to a method of purifying haptoglobin and hemopexin from the same starting material, and uses thereof..
Csl Behring Ag
|Method for high-throughput protein detection with two antibody microarrays|
The invention provides a method for detecting one or more biological ligands, where the method generally uses two arrays of biological reagents. The two arrays have two different functionalities: the first array captures the ligands on the array; and the second array delivers detecting reagents to the captured ligands.
|Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device|
Embodiments of the invention provide swallowable devices, preparations and methods for delivering therapeutic agents within the gi tract such as neutralizing proteins (np) particularly antibodies which neutralize interleukins. Many embodiments provide a swallowable device e.g., a capsule for delivering various agents into the intestinal wall (iw).
Rani Therapeutics, Llc
|Continuous process for separation of proteins|
Disclosed is a continuous process for separating or extracting proteins from a low grade mixture of a protein of interest, other proteins, impurities, and salts in a continuous simulated moving bed separation process. The invention provides for direct extraction of heme protein and plant protein from a crude mixture of such proteins, other proteins, impurities and salts using the chromatographic technique of simulated moving bed (smb) continuous chromatography.
Orochem Technologies, Inc.
|Compounds and methods for the targeted degradation of bromodomain-containing proteins|
The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a vhl ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein.
|Protein detection method using mass spectrometry|
The present invention provides: a method of pretreating a serum or plasma sample for detection of a protein or a plurality of proteins of interest in a serum or plasma sample via mass spectrometry and a method of detecting such a protein or proteins, wherein proteins such as albumin present in abundance in a sample are removed in a convenient manner, thereby making it possible to collect digested peptides from the protein of interest. Specifically, the present invention provides a method of pretreating a sample for detecting proteins in a serum or plasma sample via mass spectrometry, comprising a step of adding a protease to the sample under non-denaturing conditions to digest proteins and a step of separating the obtained peptides from undigested proteins, and a method of detecting proteins, comprising subjecting the obtained peptides to mass spectrometry..
Method of improving the movement of a target polynucleotide with respect to a transmembrane pore
The invention relates to improving the movement of a target polynucleotide with respect to a transmembrane pore when the movement is controlled by a polynucleotide binding protein. The invention also relates to improved transmembrane pores and polynucleotide binding proteins..
Oxford Nanopore Technologies Ltd.
Novel glycosyltransferase gene and use thereof
Provided is a polynucleotide for encoding a protein that exhibits activity for transferring a sugar to a hydroxyl group at position 7 of a flavone, particularly flavone 4′-glucoside. A polynucleotide selected from the group consisting of: (a) polynucleotides comprising a base sequence of seq id no.: 1 or seq id no.: 5; (b) polynucleotides that hybridize, under stringent conditions, with polynucleotides comprising a base sequence complementary to a base sequence of seq id no.: 1 or seq id no.: 5, wherein the polynucleotides encode a protein that exhibits activity for transferring a sugar to a hydroxyl group at position 7 of a flavone; (c) polynucleotides for encoding proteins comprising an amino acid sequence of seq id no.: 2 or seq id no.: 6; (d) polynucleotides for encoding proteins comprising an amino acid sequence in which one or more amino acids have been deleted, substituted, inserted, and/or added in an amino acid sequence of seq id no.: 2 or seq id no.: 6, the polynucleotides exhibiting activity for transferring a sugar to a hydroxyl group at position 7 of a flavone; and the like..
Suntory Holdings Limited
Il-1 binding proteins
Proteins that bind il-1α and il-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing il-1-related disorders and for detecting il-1α and il-1β in cells, tissues, samples, and compositions.. .
Novel glycosaminoglycan-antagonising fusion proteins and methods of using same
The present invention relates to novel monomeric fusion proteins derived from human gag binding proteins such as chemokines with increased glycosaminoglycan (gag) binding affinity and knocked-out or reduced gpcr activity compared to wild type gag binding proteins, which are highly selectively competitive and are of increased bioavailability, and to their use for prevention or treatment of pathological cell movement as in metastasis.. .
Antagonis Biotherapeutics Gmbh
Specific and high affinity binding proteins comprising modified sh3 domains of fyn kinase
The present invention relates to a method for the production of a library comprising recombinant derivatives of the sh3 domain of the fyn kinase of seq id no: 1 as well as a method for selecting from a library comprising recombinant derivatives of the sh3 domain of the fyn kinase of seq id no: 1 one or more of said derivatives having a specific binding affinity to a protein or peptide.. .
Eidgenoessische Technische Hochschule Zurich
The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a t cell response, and a second polynucleotide encoding at least one protein, peptide or variant thereof, which induces an anti-pathogenic b cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture..
Glaxosmithkline Biologicals S.a.
Engineered cellular pathways for programmed autoregulation of differentiation
The present invention provides compositions and methods for programming mammalian cells to perform desired functions. In particular, the present invention provides compositions and methods for programming stem cells to differentiate into a desired cell type.
The Trustees Of Princeton University
Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
Methods and compositions for gene disruption, gene editing or gene stacking within a fad2 loci by cleaving, in a site directed manner, a location in a fad2 gene in a soybean cell, to generate a break in the fad2 gene and then optionally integrating into the break a nucleic acid molecule of interest is disclosed.. .
Sangamo Biosciences, Inc.
Recombinant host cell for expressing proteins of interest
The present invention is in the field of recombinant biotechnology, in particular in the field of protein expression. The invention generally relates to a method of expressing a protein of interest (poi) from a host cell.
Recombinant rna particles and methods of producing proteins
The present invention provides compositions and methods for the production and delivery of recombinant double-stranded rna molecules (dsrna) encoding heterologous proteins, which can be useful for various therapeutic purposes as well as for the production of desired proteins. The compositions contain engineered double-stranded rna particles (dsrps) that can contain a double-stranded rna molecule that can be a genome or portion of a genome, which can be enclosed in a capsid or coat protein.
Synthetic Genomics, Inc.
Hybridoma cell lines (my-c-cc0c2-259-1 a4) and use thereof for producing a monoclonal antibody against human cardiac myosin binding protein c (c-protein, mybpc3, cmybp-c or my-c)
Monoclonal antibodies, which can be produced in vitro, against cardiac epitopes of the human my-c are produced by generating myeloma cell clones that produce such specific antibodies having epitope specificity. These monoclonal antibodies allow, among other things, the creation of an enzyme-linked immunosorbent assay (elisa) for the specific, cross-reactivity-free quantitative determination of my-c in serum, plasma, whole blood or other body fluid.
Martin- Luther-universitaet Halle-wittenberg
Methods of treatment using alpha-1-antitrypsin compositions
A streamlined method for purifying alpha-1-antitrypsin (aat) from an aat-containing protein mixture, such as coh fraction iv precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as dithiol, which does not affect aat.
Csl Behring L.l.c.
Vhnar anti-cytokine domains
The present invention concerns therapeutic compositions containing proteins that are the variable regions of ignar immunoglobulins, denominated vnar, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described.. .
Laboratorios Silanes S.a. De C.v.
The present invention relates to inhibitors of protein-protein interactions (ppi). Specifically, the present invention relates to a structural informatics approach to designing peptidomimetic macrocycles containing an amino acid “warhead” for ligand-directed covalent modification of cysteine and lysine-containing proteins for the treatment of diseases such as cancer.
Noliva Therapeutics Llc
Compositions and methods for treating itching, gingivostomatitis, and demodectic mange
Provided are methods for treating itching caused by allergy, include itching associated with parasite-mediated inflammation (e.g., demodicosis, stomatitis, dermatophytosis, etc.), comprising administration to a mammalian subject in need thereof a therapeutically effective amount of a heat-treated, fractionated thymus extract composition (e.g., thyex-1-6a and -6b compositions, comprising proteins or polypeptides having molecular weights in the range of 3.5 kda to 30 kda), in combination with or formulated with colostrum, to provide for reducing itching in the subject. Combination or adjunctive therapies comprising administration of a heat-treated, fractionated thymus extract composition in combination with or formulated with colostrum, and including at least one additional anti-parasitic, anti-bacterial, anti-fungal, anti-viral agent, or homeopathic agent are also provided.
Cmi Research Management, Llc
Fn14 binding proteins and uses thereof
The present disclosure provides proteins comprising antibody antigen binding domains that bind to fn14 and uses thereof. The present disclosure also provides methods for treating wasting disorders, such as cachexia..
La Trobe University
Gitr antigen binding proteins
Antigen binding proteins that activate gitr are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided.
Prolactin receptor binding proteins and uses thereof
The present invention encompasses prlr binding proteins. Specifically, the invention relates to antibodies that are chimeric, cdr grafted and humanized antibodies.
Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent.
Liquid formulations of tumor necrosis factor-binding proteins
The invention relates to a stable, pharmaceutically acceptable, aqueous formulation of tnf-binding protein, comprising a tnf-binding protein, a buffer and an isotonicity agent.. .
Ares Trading S.a.
Device for detecting misfolded proteins and methods of use thereof
The present invention relates to diagnostic devices as well as methods of using these devices for detecting proteins of interest associated with diseases or disorders in mammals. In particular, the proteins of interest may be misfolded proteins associated with certain misfolded-protein disorders in mammals including those mammals suspected of or at risk of having such disorders..
Protein labeling with cyanobenzothiazole conjugates
The invention provides compounds and methods for site-specifically labeling proteins with cyanobenzothiazole derivatives of formula i. For example, the invention provides methods for labeling the n-terminus of a protein that terminates with a cysteine residue.
Novel dna-binding proteins and uses thereof
Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel dna-binding domains, including tale dna-binding domains. Also disclosed are methods of using these novel dna-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences..
Sangamo Biosciences, Inc.
Methods and products for expressing proteins in cells
The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the dna sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic rna molecules.
Factor Bioscience Inc.
Human antigen binding proteins that bind betta-klotho, fgf receptors and complexes thereof
The present invention provides compositions and methods relating to or derived from antigen binding proteins activate fgf21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-klotho; (ii) fgfr1c, fgfr2c, fgfr3c or fgfr4; or (iii) a complex comprising β-klotho and one of fgfr1c, fgfr2c, fgfr3c, and fgfr4.
Cd86 antagonist multi-target binding proteins
This disclosure provides a multi-specific fusion protein composed of a cd86 antagonist binding domain and another binding domain that is an il-10 agonist, an hla-g agonist, an hgf agonist, an il-35 agonist, a pd-1 agonist, a btla agonist, a light antagonist, a gitrl antagonist or a cd40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains.
Aptevo Research And Development Llc
Binding proteins against vegf, pdgf, and/or their receptors
Binding proteins that bind one or more of vegf, pdgf and/or their receptors, including antibodies, cdr-grafted antibodies, humanized antibodies, binding fragments, fusion proteins, and bispecific or multispecific proteins thereof are disclosed. Also disclosed are methods of making and using the binding proteins..
Long acting proteins and peptides and methods of making and using the same
Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer ifn-γ conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to ifn-γ, particularly via a free cysteine in the protein.
Bolder Biotechnology, Inc.
Oncostatin m receptor antigen binding proteins
The invention provides anti-oncostatin m receptor-β (osmr) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. Osmr antigen binding proteins interfere with binding of osm and/or il-31 to osmr.
Kiniksa Pharmaceuticals, Ltd.
Fusion proteins comprising igg2 hinge domains
The present invention relates to biologically active fusion proteins containing the igg2 hinge as a multimerization domain capable of multimerizing proteins, peptides and small molecules which are active or more active in multimeric form; compositions comprising such fusion proteins; and methods of making and using such fusion proteins.. .
Uses of diazepane derivatives
The present invention provides compounds of formula (ii) (e.g., compounds of formula (i)), and pharmaceutically compositions thereof. Compounds of formula (ii) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (bet) proteins).
Dana-farber Cancer Institute, Inc.
Methods and compositions for the stabilization of proteins
The present disclosure relates to buffer-stabilized protein compositions and methods of making the same. The disclosed compositions and methods provide a means of stabilizing and preserving proteins or peptides in such a way that the proteins or peptides maintain their native conformation and structure, maintain biological activity, and prevent aggregation..
Method to identify compounds able to bind to the rossmann fold of c-terminal-binding proteins, identified compounds and medical uses thereof
The invention refers to a method for identifying an anti-tumoral and/or anti-proliferative and/or an inhibitor of the fission machinery involved in mitotic golgi partitioning and/or a molecule modulator of ctbp corepressor activity by testing their affinity binding for the rossmann fold of c-terminal-binding proteins (ctbps); to said identified molecules and to the use thereof as anti-proliferative and/or anti tumoral agents.. .
Consiglio Nazionale Delle Ricerche
Multi-specific binding proteins
This invention generally relates to multi-specific binding proteins. The invention also relates to methods of making such proteins and to methods of using such proteins.
Boehringer Ingelheim International Gmbh
Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.. .
St2 antigen binding proteins
Described herein are compositions and methods related to antigen binding proteins that bind to human st2, including antibodies. In particular embodiments, the disclosure provides fully human anti-st2 antibodies and deriviatives and variants thereof.
Human il-23 antigen binding proteins
Antigen binding proteins that bind to human il-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of il-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided..
Avian colony stimulating factor 1 receptor binding proteins
The present invention provides avian csf1 genes encoding proteins which bind avian colony stimulating factor 1 receptor (csf1r) and which exhibit immunomodulatory properties.. .
The University Court Of The University Of Edinburgh
Cephalopod proteins as proton conductors
The disclosed invention relates to novel materials and associated methods for conducting protons, such materials comprising cephalopod proton-conducting proteins such as reflectins. The protonic conductivity of such cephalopod proton-conducting proteins may be modulated by the application of an electric field.
The Regents Of The University Of California
Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
The present invention provides a method of treating bph using modified pore-forming proteins (mpps). These mpps are derived from naturally occurring cytotoxic proteins (npps) that kill cells by forming pores or channels in the cell membrane, resulting in cell death.
Sophiris Bio Inc.